# Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

> **NCT05066165** · PHASE1,PHASE2 · TERMINATED · sponsor: **Intellia Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **GENETIC:** Arm 1: NTLA-5001
- **GENETIC:** Arm 2: NTLA-5001

## Key facts

- **NCT ID:** NCT05066165
- **Lead sponsor:** Intellia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-17
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-08-31
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Pivoting to an allogeneic version of this program currently in preclinical development.
- **Last updated:** 2023-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066165, "Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05066165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*